{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:09:22Z","timestamp":1787504962869,"version":"build-2736575974"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00210-026-05076-4","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:18:49Z","timestamp":1770959929000},"page":"10893-10908","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Synergistic anticancer effects of tamoxifen in combination with fisetin and chrysin on breast cancer cells: insights into viability, migration, and apoptosis"],"prefix":"10.1007","volume":"399","author":[{"given":"Negar","family":"Karami-Dehkordi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayeh","family":"Reiisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehran","family":"Feizi-Dehnayebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"issue":"3","key":"5076_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031707","volume":"23","author":"N Afroze","year":"2022","unstructured":"Afroze N, Pramodh S, Shafarin J, Bajbouj K, Hamad M, Sundaram MK et al (2022) Fisetin deters cell proliferation, induces apoptosis, alleviates oxidative stress and inflammation in human cancer cells, HeLa. Int J Mol Sci 23(3):1707","journal-title":"Int J Mol Sci"},{"issue":"8","key":"5076_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0431-1","volume":"15","author":"HR Ali","year":"2014","unstructured":"Ali HR, Rueda OM, Chin S-F, Curtis C, Dunning MJ, Aparicio SAJR et al (2014) Genome-driven integrated classification of breast cancer validated in over 7,500 samples. Genome Biol 15(8):431","journal-title":"Genome Biol"},{"key":"5076_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.theriogenology.2017.07.022","volume":"104","author":"AS Amin Altawash","year":"2017","unstructured":"Amin Altawash AS, Shahneh AZ, Moravej H, Ansari M (2017) Chrysin-induced sperm parameters and fatty acid profile changes improve reproductive performance of roosters. Theriogenology 104:72\u201379","journal-title":"Theriogenology"},{"issue":"1","key":"5076_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.taap.2011.04.008","volume":"254","author":"Y Bae","year":"2011","unstructured":"Bae Y, Lee S, Kim S-H (2011) Chrysin suppresses mast cell-mediated allergic inflammation: involvement of calcium, caspase-1 and nuclear factor-\u03baB. Toxicol Appl Pharmacol 254(1):56\u201364","journal-title":"Toxicol Appl Pharmacol"},{"key":"5076_CR5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cbi.2015.08.013","volume":"240","author":"C Balta","year":"2015","unstructured":"Balta C, Herman H, Boldura OM, Gasca I, Rosu M, Ardelean A et al (2015) Chrysin attenuates liver fibrosis and hepatic stellate cell activation through TGF-\u03b2\/Smad signaling pathway. Chem Biol Interact 240:94\u2013101","journal-title":"Chem Biol Interact"},{"issue":"3","key":"5076_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1010200","volume":"19","author":"D Baptista","year":"2023","unstructured":"Baptista D, Ferreira PG, Rocha M (2023) A systematic evaluation of deep learning methods for the prediction of drug synergy in cancer. PLoS Comput Biol 19(3):e1010200","journal-title":"PLoS Comput Biol"},{"key":"5076_CR7","doi-asserted-by":"crossref","unstructured":"Bogush T, Dudko E, Bogush E, Polotsky B, Tjulandin S, Davydov M (2012) Tamoxifen non-estrogen receptor mediated molecular targets. Oncology reviews 6(2):e15-e","DOI":"10.4081\/oncol.2012.e15"},{"issue":"5","key":"5076_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.5694\/mja16.01020","volume":"207","author":"J Boyages","year":"2017","unstructured":"Boyages J (2017) Radiation therapy and early breast cancer: current controversies. Med J Aust 207(5):216\u2013222","journal-title":"Med J Aust"},{"issue":"1","key":"5076_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s11010-009-0217-z","volume":"333","author":"C-S Chien","year":"2010","unstructured":"Chien C-S, Shen K-H, Huang J-S, Ko S-C, Shih Y-W (2010) Antimetastatic potential of fisetin involves inactivation of the PI3K\/Akt and JNK signaling pathways with downregulation of MMP-2\/9 expressions in prostate cancer PC-3 cells. Mol Cell Biochem 333(1):169\u2013180","journal-title":"Mol Cell Biochem"},{"key":"5076_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114996","volume":"164","author":"RK Chinnadurai","year":"2023","unstructured":"Chinnadurai RK, Khan N, Meghwanshi GK, Ponne S, Althobiti M, Kumar R (2023) Current research status of anti-cancer peptides: mechanism of action, production, and clinical applications. Biomed Pharmacother 164:114996","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"5076_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"T-C Chou","year":"2010","unstructured":"Chou T-C (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70(2):440\u2013446","journal-title":"Cancer Res"},{"issue":"4","key":"5076_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s12609-019-00333-3","volume":"11","author":"BM Chun","year":"2019","unstructured":"Chun BM, Page DB, McArthur HL (2019) Combination immunotherapy strategies in breast cancer. Curr Breast Cancer Rep 11(4):228\u2013240","journal-title":"Curr Breast Cancer Rep"},{"issue":"4","key":"5076_CR13","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/1097-0142(19830215)51:4<581::AID-CNCR2820510404>3.0.CO;2-G","volume":"51","author":"G Cocconi","year":"1983","unstructured":"Cocconi G, De Lisi V, Boni C, Mori P, Malacarne P, Amadori D et al (1983) Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer: a prospective randomized study. Cancer 51(4):581\u20138","journal-title":"Cancer"},{"key":"5076_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-080-5","volume-title":"Cancer cell culture: methods and protocols","author":"IA Cree","year":"2011","unstructured":"Cree IA (2011) Cancer cell culture: methods and protocols. Springer"},{"issue":"8","key":"5076_CR15","doi-asserted-by":"publisher","DOI":"10.1101\/pdb.prot087171","volume":"2016","author":"LC Crowley","year":"2016","unstructured":"Crowley LC, Christensen ME, Waterhouse NJ (2016) Measuring survival of adherent cells with the colony-forming assay. Cold Spring Harb Protoc 2016(8):pdb. prot087171","journal-title":"Cold Spring Harb Protoc"},{"issue":"3","key":"5076_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.drup.2009.03.001","volume":"12","author":"P Dent","year":"2009","unstructured":"Dent P, Curiel DT, Fisher PB, Grant S (2009) Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. Drug Resist Updat 12(3):65\u201373","journal-title":"Drug Resist Updat"},{"key":"5076_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.628690","volume":"12","author":"C Dong","year":"2021","unstructured":"Dong C, Wu J, Chen Y, Nie J, Chen C (2021) Activation of PI3K\/AKT\/mTOR pathway causes drug resistance in breast cancer. Front Pharmacol 12:628690","journal-title":"Front Pharmacol"},{"issue":"3","key":"5076_CR18","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/S1470-2045(19)30026-9","volume":"20","author":"FJ Esteva","year":"2019","unstructured":"Esteva FJ, Hubbard-Lucey VM, Tang J, Pusztai L (2019) Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol 20(3):e175\u2013e186","journal-title":"Lancet Oncol"},{"issue":"4","key":"5076_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041225","volume":"15","author":"MA Faheem","year":"2023","unstructured":"Faheem MA, Akhtar T, Naseem N, Aftab U, Zafar MS, Hussain S et al (2023) Chrysin is immunomodulatory and anti-inflammatory against complete Freund\u2019s adjuvant-induced arthritis in a pre-clinical rodent model. Pharmaceutics 15(4):1225","journal-title":"Pharmaceutics"},{"key":"5076_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2025.127475","volume":"428","author":"M Feizi-Dehnayebi","year":"2025","unstructured":"Feizi-Dehnayebi M, Ziarani GM, Lohith T, Ghareghomi S, Panahande Z, Farsadrooh M et al (2025) Probing the biological activity of isatin derivatives against human lung cancer A549 cells: cytotoxicity, CT-DNA\/BSA binding, DFT\/TD-DFT, topology, ADME-Tox, docking and dynamic simulations. J Mol Liq 428:127475","journal-title":"J Mol Liq"},{"issue":"3","key":"5076_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/bjc.2012.581","volume":"108","author":"R Fisher","year":"2013","unstructured":"Fisher R, Pusztai L, Swanton C (2013) Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 108(3):479\u2013485","journal-title":"Br J Cancer"},{"issue":"1","key":"5076_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/2211738507666190122111224","volume":"7","author":"FA Fisusi","year":"2019","unstructured":"Fisusi FA, Akala EO (2019) Drug combinations in breast cancer therapy. Pharm Nanotechnol 7(1):3\u201323","journal-title":"Pharm Nanotechnol"},{"issue":"9","key":"5076_CR23","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1002\/bjs.10899","volume":"105","author":"CA Fleming","year":"2018","unstructured":"Fleming CA, Heneghan HM, O\u2019Brien D, McCartan DP, McDermott EW, Prichard RS (2018) Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. Br J Surg 105(9):1098\u20131106","journal-title":"Br J Surg"},{"issue":"2","key":"5076_CR24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1148\/21.2.156","volume":"21","author":"EH Grubb\u00e9","year":"1933","unstructured":"Grubb\u00e9 EH (1933) Priority in the therapeutic use of X-rays. Radiology 21(2):156\u2013162","journal-title":"Radiology"},{"key":"5076_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2019.00697","volume":"7","author":"G Grynkiewicz","year":"2019","unstructured":"Grynkiewicz G, Demchuk O (2019) New perspectives for fisetin. Front Chem 7:697","journal-title":"Front Chem"},{"key":"5076_CR26","doi-asserted-by":"crossref","unstructured":"Hussain Y, Khan H, Alam W, Aschner M, Abdullah, Alsharif KF et al (2022) Flavonoids targeting the mTOR signaling cascades in cancer: a potential crosstalk in anti\u2010breast cancer therapy. Oxid Med Cell Longev 2022(1):4831833","DOI":"10.1155\/2022\/4831833"},{"issue":"8","key":"5076_CR27","volume":"8","author":"S Jamshidi","year":"2025","unstructured":"Jamshidi S, Eghbalian A, Shojaei S, Taherkhani A, Feizi\u2010Dehnayebi M (2025) Flavonoids as promising Akt1 inhibitors in cancer medicine: insights from molecular docking, dynamics, DFT calculations, and in vitro validation. Cancer Rep 8(8):e70315","journal-title":"Cancer Rep"},{"issue":"9","key":"5076_CR28","doi-asserted-by":"publisher","first-page":"7134","DOI":"10.1002\/jcp.26532","volume":"233","author":"LB Jeng","year":"2018","unstructured":"Jeng LB, Kumar Velmurugan B, Chen MC, Hsu HH, Ho TJ, Day CH et al (2018) Fisetin mediated apoptotic cell death in parental and oxaliplatin\/irinotecan resistant colorectal cancer cells in vitro and in vivo. J Cell Physiol 233(9):7134\u20137142","journal-title":"J Cell Physiol"},{"issue":"7","key":"5076_CR29","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1245\/s10434-019-07291-1","volume":"26","author":"VC Jordan","year":"2019","unstructured":"Jordan VC (2019) The SERM saga, something from nothing: American Cancer Society\/SSO basic science lecture. Ann Surg Oncol 26(7):1981\u20131990","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"5076_CR30","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s11626-014-9830-6","volume":"51","author":"KA Kang","year":"2015","unstructured":"Kang KA, Piao MJ, Hyun JW (2015) Fisetin induces apoptosis in human nonsmall lung cancer cells via a mitochondria-mediated pathway. In Vitro Cell Dev Biol Anim 51(3):300\u2013309","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"5076_CR31","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.biopha.2018.06.105","volume":"105","author":"AA Khamis","year":"2018","unstructured":"Khamis AA, Ali EM, Abd El-Moneim MA, Abd-Alhaseeb MM, El-Magd MA, Salim EI (2018) Hesperidin, piperine and bee venom synergistically potentiate the anticancer effect of tamoxifen against breast cancer cells. Biomed Pharmacother 105:1335\u20131343","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"5076_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-50729-6","volume":"14","author":"AA Khamis","year":"2024","unstructured":"Khamis AA, Ali EM, Salim EI, El-Moneim MAA (2024) Synergistic effects of bee venom, hesperidin, and piperine with tamoxifen on apoptotic and angiogenesis biomarker molecules against xerographic MCF-7 injected rats. Sci Rep 14(1):1510","journal-title":"Sci Rep"},{"issue":"6","key":"5076_CR33","doi-asserted-by":"publisher","DOI":"10.1101\/pdb.prot095505","volume":"2018","author":"P Kumar","year":"2018","unstructured":"Kumar P, Nagarajan A, Uchil PD (2018) Analysis of cell viability by the MTT assay. Cold Spring Harb Protoc 2018(6):pdb. prot095505","journal-title":"Cold Spring Harb Protoc"},{"key":"5076_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.723147","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y, Wang K, Chen Y, Cai J, Qin X, Lu A et al (2021) A system pharmacology model for decoding the synergistic mechanisms of compound Kushen injection in treating breast cancer. Front Pharmacol 12:723147","journal-title":"Front Pharmacol"},{"issue":"2","key":"5076_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s13167-021-00242-5","volume":"12","author":"A Liskova","year":"2021","unstructured":"Liskova A, Samec M, Koklesova L, Brockmueller A, Zhai K, Abdellatif B et al (2021) Flavonoids as an effective sensitizer for anti-cancer therapy: insights into multi-faceted mechanisms and applicability towards individualized patient profiles. EPMA J 12(2):155\u2013176","journal-title":"EPMA J"},{"issue":"1","key":"5076_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02165-x","volume":"23","author":"S Liu","year":"2024","unstructured":"Liu S, Zhang X, Wang W, Li X, Sun X, Zhao Y et al (2024) Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer. Mol Cancer 23(1):261","journal-title":"Mol Cancer"},{"issue":"4","key":"5076_CR37","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212 \u0394\u0394CT method. methods 25(4):402\u20138","journal-title":"methods"},{"key":"5076_CR38","doi-asserted-by":"publisher","DOI":"10.5530\/ijpi.14.4.122","author":"CL Lobo","year":"2024","unstructured":"Lobo CL, Prabhu PP, Dubey A, Shetty A, Mahadev M (2024) Exploring the potential of hesperidin and synergistic formulations in breast cancer management: a comprehensive review. Int J Pharm Investig. https:\/\/doi.org\/10.5530\/ijpi.14.4.122","journal-title":"Int J Pharm Investig"},{"issue":"6","key":"5076_CR39","first-page":"285","volume":"3","author":"S Loewe","year":"1953","unstructured":"Loewe S (1953) The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3(6):285\u2013290","journal-title":"Arzneimittelforschung"},{"key":"5076_CR40","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.phytochem.2017.09.016","volume":"145","author":"R Mani","year":"2018","unstructured":"Mani R, Natesan V (2018) Chrysin: sources, beneficial pharmacological activities, and molecular mechanism of action. Phytochemistry 145:187\u2013196","journal-title":"Phytochemistry"},{"issue":"7467","key":"5076_CR41","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nature12624","volume":"501","author":"CE Meacham","year":"2013","unstructured":"Meacham CE, Morrison SJ (2013) Tumour heterogeneity and cancer cell plasticity. Nature 501(7467):328\u2013337","journal-title":"Nature"},{"key":"5076_CR42","doi-asserted-by":"crossref","unstructured":"Morgan DM (1998) Tetrazolium (MTT) assay for cellular viability and activity. Polyamine protocols. Springer, pp 179\u201384","DOI":"10.1385\/0-89603-448-8:179"},{"issue":"16","key":"5076_CR43","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS et al (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30(16):2785\u20132791","journal-title":"J Comput Chem"},{"issue":"7","key":"5076_CR44","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1517\/14656566.6.7.1073","volume":"6","author":"J-M Nabholtz","year":"2005","unstructured":"Nabholtz J-M, Gligorov J (2005) The role of taxanes in the treatment of breast cancer. Expert Opin Pharmacother 6(7):1073\u20131094","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"5076_CR45","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10549-006-9335-4","volume":"102","author":"UW Nilsson","year":"2007","unstructured":"Nilsson UW, Garvin S, Dabrosin C (2007) MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells. Breast Cancer Res Treat 102(3):253\u2013261","journal-title":"Breast Cancer Res Treat"},{"key":"5076_CR46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ejphar.2015.06.038","volume":"764","author":"E-M Noh","year":"2015","unstructured":"Noh E-M, Park Y-J, Kim J-M, Kim M-S, Kim H-R, Song H-K et al (2015) Fisetin regulates TPA-induced breast cell invasion by suppressing matrix metalloproteinase-9 activation via the PKC\/ROS\/MAPK pathways. Eur J Pharmacol 764:79\u201386","journal-title":"Eur J Pharmacol"},{"issue":"21","key":"5076_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/nu16213741","volume":"16","author":"N Or\u0161oli\u0107","year":"2024","unstructured":"Or\u0161oli\u0107 N, Jazvin\u0161\u0107ak Jembrek M (2024) Potential strategies for overcoming drug resistance pathways using propolis and its polyphenolic\/flavonoid compounds in combination with chemotherapy and radiotherapy. Nutrients 16(21):3741","journal-title":"Nutrients"},{"key":"5076_CR48","doi-asserted-by":"crossref","unstructured":"Oyewole AO, Birch-Machin MA (2015) Mitochondria-targeted antioxidants. The FASEB J 29(12):4766\u20134771","DOI":"10.1096\/fj.15-275404"},{"issue":"1","key":"5076_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/npjbcancer.2016.24","volume":"2","author":"RK Potkul","year":"2016","unstructured":"Potkul RK, Unger JM, Livingston RB, Crew KD, Wilczynski SP, Salomon CG et al (2016) Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630. NPJ Breast Cancer 2(1):16024","journal-title":"NPJ Breast Cancer"},{"key":"5076_CR50","unstructured":"Rodriguez LG, Wu X, Guan J-L (2005) Wound-healing assay. Cell migration: developmental methods and protocols. Springer, pp 23\u20139"},{"issue":"17","key":"5076_CR51","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1001\/jama.2019.3927","volume":"321","author":"KJ Ruddy","year":"2019","unstructured":"Ruddy KJ, Ganz PA (2019) Treatment of nonmetastatic breast cancer. JAMA 321(17):1716\u20131717","journal-title":"JAMA"},{"issue":"6","key":"5076_CR52","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2174\/1871520614666140209144042","volume":"14","author":"S Samarghandian","year":"2014","unstructured":"Samarghandian S, Nezhad MA, Mohammadi G (2014) Role of caspases, Bax and Bcl-2 in chrysin-induced apoptosis in the A549 human lung adenocarcinoma epithelial cells. Anticancer Agents Med Chem 14(6):901\u2013909","journal-title":"Anticancer Agents Med Chem"},{"key":"5076_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1469441","volume":"15","author":"S Sisodiya","year":"2024","unstructured":"Sisodiya S, Kasherwal V, Rani J, Mishra N, Kumar S, Khan A et al (2024) Impact of combinatorial immunotherapies in breast cancer: a systematic review and meta-analysis. Front Immunol 15:1469441","journal-title":"Front Immunol"},{"issue":"3","key":"5076_CR54","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2024.00230","volume":"5","author":"A Sood","year":"2024","unstructured":"Sood A, Mehrotra A, Sharma U, Aggarwal D, Singh T, Shahwan M et al (2024) Advancements and recent explorations of anti-cancer activity of chrysin: from molecular targets to therapeutic perspective. Exploration of Targeted Anti-Tumor Therapy 5(3):477","journal-title":"Exploration of Targeted Anti-Tumor Therapy"},{"key":"5076_CR55","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/j.proeng.2012.07.595","volume":"42","author":"M Stoia","year":"2012","unstructured":"Stoia M, Oancea S (2012) Workplace health promotion program on using dietary antioxidants (anthocyanins) in chemical exposed workers. Procedia Eng 42:1989\u20131996","journal-title":"Procedia Eng"},{"issue":"11","key":"5076_CR56","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.7150\/ijbs.21635","volume":"13","author":"Y-S Sun","year":"2017","unstructured":"Sun Y-S, Zhao Z, Yang Z-N, Xu F, Lu H-J, Zhu Z-Y et al (2017) Risk factors and preventions of breast cancer. Int J Biol Sci 13(11):1387","journal-title":"Int J Biol Sci"},{"issue":"6","key":"5076_CR57","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1124\/mol.107.034512","volume":"71","author":"B Sung","year":"2007","unstructured":"Sung B, Pandey MK, Aggarwal BB (2007) Fisetin, an inhibitor of cyclin-dependent kinase 6, down-regulates nuclear factor-\u03baB-regulated cell proliferation, antiapoptotic and metastatic gene products through the suppression of TAK-1 and receptor-interacting protein-regulated I\u03baB\u03b1 kinase activation. Mol Pharmacol 71(6):1703\u20131714","journal-title":"Mol Pharmacol"},{"key":"5076_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00916","volume":"8","author":"V Suvarna","year":"2017","unstructured":"Suvarna V, Murahari M, Khan T, Chaubey P, Sangave P (2017) Phytochemicals and PI3K inhibitors in cancer\u2014an insight. Front Pharmacol 8:916","journal-title":"Front Pharmacol"},{"issue":"2","key":"5076_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0298788","volume":"19","author":"K Taoma","year":"2024","unstructured":"Taoma K, Ruengjitchatchawalya M, Liangruksa M, Laomettachit T (2024) Boolean modeling of breast cancer signaling pathways uncovers mechanisms of drug synergy. PLoS ONE 19(2):e0298788","journal-title":"PLoS ONE"},{"issue":"4","key":"5076_CR60","doi-asserted-by":"publisher","first-page":"455","DOI":"10.7326\/0003-4819-104-4-455","volume":"104","author":"IVSG Taylor","year":"1986","unstructured":"Taylor IVSG, Gelman RS, Falkson G, Cummings FJ (1986) Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med 104(4):455\u201361","journal-title":"Ann Intern Med"},{"key":"5076_CR61","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.fct.2018.07.059","volume":"120","author":"C-F Tsai","year":"2018","unstructured":"Tsai C-F, Chen J-H, Chang C-N, Lu D-Y, Chang P-C, Wang S-L et al (2018) Fisetin inhibits cell migration via inducing HO-1 and reducing MMPs expression in breast cancer cell lines. Food Chem Toxicol 120:528\u2013535","journal-title":"Food Chem Toxicol"},{"issue":"10","key":"5076_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/ph18101486","volume":"18","author":"P Uniyal","year":"2025","unstructured":"Uniyal P, Akhtar A, Rawat R (2025) Flavonoid-based combination therapies and nano-formulations: an emerging frontier in breast cancer treatment. Pharmaceuticals 18(10):1486","journal-title":"Pharmaceuticals"},{"key":"5076_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00359","volume":"9","author":"WJ Van Weelden","year":"2019","unstructured":"Van Weelden WJ, Massuger LF, Pijnenborg JM, Romano A (2019) Anti-estrogen treatment in endometrial cancer: a systematic review. Front Oncol 9:359","journal-title":"Front Oncol"},{"issue":"1","key":"5076_CR64","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0022-1759(95)00072-I","volume":"184","author":"I Vermes","year":"1995","unstructured":"Vermes I, Haanen C, Steffens-Nakken H, Reutellingsperger C (1995) A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods 184(1):39\u201351","journal-title":"J Immunol Methods"},{"issue":"1","key":"5076_CR65","first-page":"81","volume":"3","author":"IIIHJ Wallace","year":"2003","unstructured":"Wallace IIIHJ (2003) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy and lumpectomy plus irradiation for the treament of invasive breast cancer. Womens Oncol Rev 3(1):81","journal-title":"Womens Oncol Rev"},{"key":"5076_CR66","doi-asserted-by":"crossref","unstructured":"Wang PP, He CX, Shuai YY, Zhang HJ, Zhang L, Ao H et al (2025) The combination of natural products: a promising therapeutical way for management of breast cancers. Phytother Res","DOI":"10.1002\/ptr.70044"},{"key":"5076_CR67","volume-title":"World cancer report 2014","author":"CP Wild","year":"2014","unstructured":"Wild CP, Stewart BW, Wild C (2014) World cancer report 2014. World Health Organization, Geneva, Switzerland"},{"key":"5076_CR68","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.theriogenology.2019.11.008","volume":"148","author":"D Wolak","year":"2020","unstructured":"Wolak D, Hrabia A (2020) Tamoxifen-induced alterations in the expression of selected matrix metalloproteinases (MMP-2, -9, -10, and\u00a0-13) and their tissue inhibitors (TIMP-2 and -3) in the chicken ovary. Theriogenology 148:208\u2013215","journal-title":"Theriogenology"},{"issue":"4","key":"5076_CR69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124007","volume":"10","author":"Y Xia","year":"2015","unstructured":"Xia Y, Lian S, Khoi PN, Yoon HJ, Joo YE, Chay KO et al (2015) Chrysin inhibits tumor promoter-induced MMP-9 expression by blocking AP-1 via suppression of ERK and JNK pathways in gastric cancer cells. PLoS One 10(4):e0124007","journal-title":"PLoS One"},{"key":"5076_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.847113","volume":"13","author":"C Yen","year":"2022","unstructured":"Yen C, Zhao F, Yu Z, Zhu X, Li CG (2022) Interactions between natural products and tamoxifen in breast cancer: a comprehensive literature review. Front Pharmacol 13:847113","journal-title":"Front Pharmacol"},{"key":"5076_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/biom13010093","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, Long H, Zhou Z, Fu Y, Jiang B (2023) PI3K-AKT-targeting breast cancer treatments: natural products and synthetic compounds. Biomolecules. https:\/\/doi.org\/10.3390\/biom13010093","journal-title":"Biomolecules"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05076-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05076-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05076-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:03:42Z","timestamp":1782101022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05076-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":71,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["5076"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05076-4","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"15 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}